Disease · MONDO_0005371

mood disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. mood disorder. Diseases, record MONDO_0005371. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005371

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: mood disorder; Open Targets
Open Targets ID: MONDO_0005371; Open Targets
Other names: affective disorders, major mood disorders, mood disorders; Open Targets
Disease Ontology: DOID:3324; Disease Ontology
MeSH: D019964; MeSH
NCI Thesaurus: C92200; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 52 drugs, from DailyMed and TTD; Open Targets

Drugs52

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BUPROPION HYDROCHLORIDE	CHEMBL1698	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
FLIBANSERIN	CHEMBL231068	Small molecule	Approval	TTD	1	0	0	Drugs and targets
ESTROGEN	CHEMBL592868	Small molecule	Phase 3	ClinicalTrials.gov	2	2	1	Drugs and targets
LAMOTRIGINE	CHEMBL741	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
TESTOSTERONE	CHEMBL386630	Small molecule	Phase 3	ClinicalTrials.gov	2	2	1	Drugs and targets
ESTRADIOL VALERATE	CHEMBL1511	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
LIRAGLUTIDE	CHEMBL4084119	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
METHYLPHENIDATE	CHEMBL796	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
NALTREXONE	CHEMBL19019	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
QUETIAPINE	CHEMBL716	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 52

See all 52 drugs

Targets89

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SLC6A2	Monoamine transporter	6	Monoamine transporter inhibitor; Norepinephrine transporter inhibitor; Sodium-dependent noradrenaline transporter releasing agent	Approval	https://conductscience.org/library/genes/6530	Drugs and targets
SLC6A3	Monoamine transporter	6	Dopamine transporter inhibitor; Monoamine transporter inhibitor; Sodium-dependent dopamine transporter releasing agent	Approval	https://conductscience.org/library/genes/6531	Drugs and targets
SLC6A4	Monoamine transporter	5	Monoamine transporter inhibitor; Serotonin transporter inhibitor; Sodium-dependent serotonin transporter releasing agent	Phase 3	https://conductscience.org/library/genes/6532	Drugs and targets
HTR1A	5-hydroxytryptamine receptor 1A	4	Serotonin 1a (5-HT1a) receptor agonist; Serotonin 1a (5-HT1a) receptor antagonist	Phase 3	https://conductscience.org/library/genes/3350	Drugs and targets
ALDH5A1	Succinate-semialdehyde dehydrogenase, mitochondrial	2	Succinate semialdehyde dehydrogenase inhibitor	Phase 3	https://conductscience.org/library/genes/7915	Drugs and targets
CHRNA4	Neuronal acetylcholine receptor; alpha4/beta2	2	Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 antagonist	Phase 1	https://conductscience.org/library/genes/1137	Drugs and targets
CHRNB2	Neuronal acetylcholine receptor; alpha4/beta2	2	Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 antagonist	Phase 1	https://conductscience.org/library/genes/1141	Drugs and targets
CNR1	Cannabinoid receptor 1	2	Cannabinoid CB1 receptor agonist; Cannabinoid CB1 receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/1268	Drugs and targets
ESR1	Estrogen receptor	2	Estrogen receptor alpha agonist	Phase 3	https://conductscience.org/library/genes/2099	Drugs and targets
HTR2A	5-hydroxytryptamine receptor 2A	2	Serotonin 2a (5-HT2a) receptor agonist; Serotonin 2a (5-HT2a) receptor antagonist	Phase 3	https://conductscience.org/library/genes/3356	Drugs and targets

1 to 10 of 89

See all 89 targets

Trials21

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01928758	Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders	Not applicable	245	2019-02-08	Tobacco Dependence	(+/-)NICOTINE, NICOTINE	Its record names the disease	ClinicalTrials.gov
NCT00579982	An Open-Label Trial Measuring Satisfaction And Convenience Of Two Formulations Of Lamotrigine In Subjects With A Mood Disorder	Phase 3	97	2009-08-03	Mood Disorders	LAMOTRIGINE	Its record names the disease	ClinicalTrials.gov
NCT01342549	Treatment Strategy for Alcohol Use Disorders in Veterans With TBI	Phase 3	62	2016-06-09	Alcohol Dependence	NALTREXONE, VALPROIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00463450	Efficacy of Gynodian® Depot in Women With Impaired Well-being	Phase 3	140		Hormone Replacement Therapy	ESTRADIOL VALERATE	Its record names the disease	ClinicalTrials.gov
NCT05469243	Psychedelic Therapy for Wellness Studies Retrospectively		100		Well Aging	KETAMINE, MIDOMAFETAMINE, N,N-DIMETHYLTRYPTAMINE, PSILOCYBIN	Its record names the disease	ClinicalTrials.gov
NCT07296874	Acute Effects of Cannabis on Cognition and Affect	Phase 1	92		Cannabis Use	DRONABINOL	Its record names the disease	ClinicalTrials.gov
NCT05832489	EEG-MRI Imaging of Methylphenidate Effects in Adult ADHD and Attentional Symptoms in Mood Disorders	Phase 3	80		Adult ADHD, Adult-onset ADHD With Mood Disorder	METHYLPHENIDATE	Its record names the disease	ClinicalTrials.gov
NCT00001482	New Drugs in the Treatment of Mood Disorders	Phase 2	60		Anxiety Disorder, Mood Disorder, Psychotic Disorder	GABAPENTIN, LAMOTRIGINE	Its record names the disease	ClinicalTrials.gov
NCT06305182	Metreleptin in Anorexia Nervosa	Phase 2	50		Anorexia Nervosa	METRELEPTIN	Its record names the disease	ClinicalTrials.gov
NCT04439825	Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction	Phase 1	45		Mood	ONABOTULINUMTOXINA	Its record names the disease	ClinicalTrials.gov

1 to 10 of 21

See all 21 trials

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Reduced Nicotine Content Cigarettes vs Usual Nicotine Content Cigarettes: Abstinence From Smoking	17 of 94	4 of 94	188	NCT01928758	Trial comparisons
Reduced Nicotine Content Cigarettes vs Usual Nicotine Content Cigarettes: deaths from any cause	0 of 94	0 of 94	188	NCT01928758	Trial comparisons
Reduced Nicotine Content Cigarettes vs Usual Nicotine Content Cigarettes: serious adverse events	7 of 94	10 of 94	188	NCT01928758	Trial comparisons
Reduced Nicotine Content Cigarettes vs Usual Nicotine Content Cigarettes: Intention to Quit Smoking	33 of 69	25 of 74	143	NCT01928758	Trial comparisons
Arm 1 vs Arm 2: serious adverse events	0 of 31	0 of 31	62	NCT01342549	Trial comparisons

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
26044342	RESULT	1	PubMed
36322562	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005371

GET https://conductscience.org/api/diseases/v1/MONDO_0005371/drugs?page=2

API reference For AI assistants